On Monday, Humacyte Inc (NASDAQ: HUMA) was -4.67% drop from the session before settling in for the closing price of $1.07. A 52-week range for HUMA has been $1.04 – $5.66.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 42.43%. When this article was written, the company’s average yearly earnings per share was at 76.74%. With a float of $163.06 million, this company’s outstanding shares have now reached $193.00 million.
Humacyte Inc (HUMA) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Humacyte Inc stocks. The insider ownership of Humacyte Inc is 15.51%, while institutional ownership is 23.96%. The most recent insider transaction that took place on Aug 19 ’25, was worth 1,793,000. In this transaction Director of this company sold 1,100,000 shares at a rate of $1.63, taking the stock ownership to the 591,685 shares. Before that another transaction happened on Aug 18 ’25, when Company’s Director sold 549,360 for $1.83, making the entire transaction worth $1,005,329. This insider now owns 1,691,685 shares in total.
Humacyte Inc (HUMA) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.21 earnings per share (EPS) during the time that was better than consensus figure (set at -0.25) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 76.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 51.26% during the next five years compared to 42.43% growth over the previous five years of trading.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
You can see what Humacyte Inc (HUMA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 125.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.24, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.45 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
Compared to the last year’s volume of 4.34 million, its volume of 4.58 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 10.14%.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 0.57%, which indicates a significant decrease from 3.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0799 in the past 14 days, which was lower than the 0.1240 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3394, while its 200-day Moving Average is $1.8300. Nevertheless, the first resistance level for the watch stands at $1.0500 in the near term. At $1.0800, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.1000. If the price goes on to break the first support level at $1.0000, it is likely to go to the next support level at $0.9800. Should the price break the second support level, the third support level stands at $0.9500.
Humacyte Inc (NASDAQ: HUMA) Key Stats
There are 187,271K outstanding shares of the company, which has a market capitalization of 196.86 million. As of now, sales total 0 K while income totals -148,700 K. Its latest quarter income was 750 K while its last quarter net income were -17,510 K.
